Articles

Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines.   Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively small European Union member state…

Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its Presidency Programme, Belgium has highlighted health as one of its 14 focus areas, with the hope of strengthening the three tenets of ‘preparedness,’ ‘care,’ and…

Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is needed to drive better outcomes for their members as well as for the overall healthcare ecosystem.   Innovative Pharma: Building Trust via Dialogue For pharma.be’s…

Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field – played a vital role in the development, production, and distribution of COVID-19 vaccines over the past three years. An ecosystem of start-ups and service providers…

Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he helped co-found in 1999, Galapagos.   Stoffels is a heavyweight of the global pharmaceutical industry and close ally of the legendary Dr Paul Janssen, under…

Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off of its consumer healthcare branch. This massive growth plan involves both existing products as well as new CAR-T and autoimmune disease therapies with Belgium –…

Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the care cycle.   Patients are often left to navigate these challenges on their own, without a system in place to guide them through their journey…